Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion



Status:Recruiting
Conditions:Orthopedic, Orthopedic
Therapuetic Areas:Orthopedics / Podiatry
Healthy:No
Age Range:60 - Any
Updated:3/10/2019
Start Date:August 30, 2017
End Date:September 1, 2021
Contact:Christa Black, MPH
Email:christa.black@promedica.org
Phone:419-291-3441

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Evaluating the Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion in Hip Fracture Patients

Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty
to reduce the need for intraoperative and postoperative blood transfusions. Limited research
is available on its use in hip fracture patients. We hypothesize that the use of TXA
preoperatively, perioperatively, and postoperatively will decrease blood loss and need for
blood transfusion postoperatively.


Inclusion Criteria:

- Over the age of 60 years

- Hip fracture requiring surgical intervention

- Signs consent and agrees to participate

Exclusion Criteria:

- Under the age of 60

- Does not sign consent or refuses participation

- Known hypersensitivity to tranexamic acid

- Multiple acute fractures

- Creatinine clearance <30

- History of seizures

- Active hormone therapy

- History of coagulation abnormality

- History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last year
or history or recurrent DVT/PE

- Myocardial infarction (MI) and/or stents within the past year

- History of intracranial hemorrhage

- Acquired defective color vision

- Patients admitted directly to nursing units or surgery without stay in the Emergency
Center

- Patients who sustain fracture while hospitalized at ProMedica Toledo Hospital
We found this trial at
1
site
ProMedica Toledo Hospital
Toledo, Ohio 43606
Phone: 419-291-3858
?
mi
from
Toledo, OH
Click here to add this to my saved trials